Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × lortalamine × Genitourinary × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1 Disease 1

Interventions

Docetaxel 389 pembrolizumab 324 Prednisone 284 Gemcitabine 270 enzalutamide 252 Radiotherapy 251 Nivolumab 247 Magnetic Resonance Spectroscopy 245 Cisplatin 207 Abiraterone Acetate 197 Radiosurgery 183 Leuprolide 182 Sunitinib 169 Carboplatin 162 bicalutamide 146 Goserelin 145 Androgen Antagonists 139 Specimen Handling 136 Ipilimumab 127 Paclitaxel 126 Cyclophosphamide 116 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 110 Bevacizumab 109 Everolimus 107 apalutamide 98 cabozantinib 97 Sorafenib 97 atezolizumab 96 abiraterone 95 Radiation 89

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02615067 2019-04-10

proSPECT-AS

Molecular Insight Pharmaceuticals, Inc.

Phase 3 Completed

Disease, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡